On April 11, 2025 Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular mRNA technology for next generation nucleic acid medicine, reported that its subsidiary Circio AB has entered a research evaluation agreement with Lonza, one of the world’s largest contract development and manufacturing organizations (Press release, Circio, APR 11, 2025, View Source [SID1234651886]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research license enables Circio to test the circVec circular mRNA expression technology in Lonza’s proprietary transient expression system for protein production. Further updates will follow as necessary as the project progresses.